Roche: Bank of America raises its buy rating

(CercleFinance.com) – Bank of America announced on Friday that it had raised its recommendation on Roche shares from ‘neutral’ to ‘buy’, with a price target raised from 290 to 340 Swiss francs.

Beyond the Swiss pharmaceutical laboratory’s franchise in obesity, the analyst says he is particularly interested in the potential of three drug projects, which he believes could generate sales of more than five billion dollars.

These are, in this case, Giredestrant (breast cancer), Fenebrutinib (multiple sclerosis) and Prasinezumab (Parkinson’s disease), the intermediary indicates in a note.

Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyses disseminated by Cercle Finance are only a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of the information and analyses by readers. Any uninformed person is advised to consult a professional advisor before making any investment. This indicative information does not in any way constitute an incentive to sell or a solicitation to buy.

Did you like this article? Share it with your friends using the buttons below.